BCa isn't my best area, but a couple of observations...
600mg bid is a LOT of drug. It will be interesting to see how this performs in broader patient populations.
They have a future trial design problem trying to figure out how to deal with T-DM1 in terms of choosing a path to approval. What have they guided for their next trial indication and design?
Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC. We're on Twitter at BiotechStockRsr
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.